Tenaya Therapeutics Stock Beneish M Score

TNYA Stock  USD 3.58  0.01  0.28%   
This module uses fundamental data of Tenaya Therapeutics to approximate the value of its Beneish M Score. Tenaya Therapeutics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Tenaya Therapeutics Piotroski F Score and Tenaya Therapeutics Altman Z Score analysis.
For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.
  
At present, Tenaya Therapeutics' Debt To Equity is projected to increase slightly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.03, whereas Net Debt is forecasted to decline to (34.9 M). At present, Tenaya Therapeutics' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 1.80, whereas Book Value Per Share is forecasted to decline to 1.12.
At this time, it appears that Tenaya Therapeutics is an unlikely manipulator. The earnings manipulation may begin if Tenaya Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Tenaya Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Tenaya Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-5.31
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

N/A

Focus
Asset Quality

0.65

Focus
Expense Coverage

N/A

Focus
Gross Margin Strengs

N/A

Focus
Accruals Factor

N/A

Focus
Depreciation Resistance

0.99

Focus
Net Sales Growth

N/A

Focus
Financial Leverage Condition

1.38

Focus

Tenaya Therapeutics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Tenaya Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables1.8 MM
Fairly Down
Slightly volatile
Total Assets209 M170.5 M
Fairly Up
Slightly volatile
Total Current Assets158 M111.6 M
Significantly Up
Slightly volatile
Non Current Assets Total50.9 M58.9 M
Fairly Down
Slightly volatile
Property Plant Equipment33.2 M58.7 M
Way Down
Slightly volatile
Depreciation And AmortizationM8.7 M
Way Down
Slightly volatile
Selling General Administrative20.9 M33.2 M
Way Down
Slightly volatile
Total Current Liabilities17.1 M22.7 M
Way Down
Slightly volatile
Non Current Liabilities Total7.9 M8.4 M
Notably Down
Slightly volatile
Short Term Debt7.6 M8.6 M
Fairly Down
Slightly volatile

Tenaya Therapeutics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Tenaya Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Tenaya Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Tenaya Therapeutics' degree of accounting gimmicks and manipulations.

About Tenaya Therapeutics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

4.97 Million

At present, Tenaya Therapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting.

Tenaya Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tenaya Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tenaya Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

About Tenaya Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tenaya Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tenaya Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tenaya Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Tenaya Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tenaya Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tenaya Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tenaya Therapeutics Stock:
Check out Tenaya Therapeutics Piotroski F Score and Tenaya Therapeutics Altman Z Score analysis.
For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.44)
Return On Assets
(0.46)
Return On Equity
(0.84)
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.